Gilead Sciences presented data from two Phase 3 studies evaluating the safety and efficacy of Genvoya for the treatment of HIV-1 infection in treatment-naïve adults at the 2017 Conference on Retroviruses and Opportunistic Infections (CROI) in Seattle.
Presenting results, Gilead said that through week 144, Genvoya demonstrated significantly higher rates of virologic suppression compared to Gilead’s Stribild, based on the percentage of patients with HIV-1 RNA levels less than 50 copies/mL. Patients receiving Genvoya also demonstrated favorable renal and bone laboratory parameters compared to those treated with Stribild.
As the company explained, Genvoya is indicated as a complete regimen for the treatment of HIV-1 infection in adults and pediatric patients 12 years of age and older who have no antiretroviral treatment history or to replace the current antiretroviral regimen in those who are virologically suppressed on a stable antiretroviral regimen for at least six months with no history of treatment failure and no known resistance to the components of Genvoya.
Jose Arribas, MD, Associated Professor of Medicine, Hospital La Paz, IdiPAZ, Madrid, Spain and the lead study investigator said: “As people grow older with HIV, physicians are increasingly looking for highly effective medications that may help address the evolving needs of their patients who face a lifetime of antiretroviral therapy.”